Skip to content

FATE THERAPEUTICS INC: 10-Q filed 2026-08-13

What FATE THERAPEUTICS INC reported in its quarterly report filed 2026-08-13 (fiscal Q2 2026): 35 published measures, 99 facts as tagged in accession 0001193125-26-347988.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-13
Fiscal period
fiscal Q2 2026
Accession
0001193125-26-347988 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All FATE THERAPEUTICS INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-30260,103,000USD
At 2025-12-31318,937,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-30153,438,000USD
At 2026-03-31179,707,000USD
At 2025-12-31207,184,000USD
At 2025-06-30261,364,000USD
At 2025-03-31288,409,000USD
At 2024-12-31318,726,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-3032,429,000USD
At 2025-12-3146,628,000USD
At 2025-06-3041,249,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-30,159,000USD91
2026-01-01 to 2026-06-30-61,372,000USD181
2026-01-01 to 2026-03-31-31,213,000USD90
2025-04-01 to 2025-06-30-34,070,000USD91
2025-01-01 to 2025-06-30-71,691,000USD181
2025-01-01 to 2025-03-31-37,621,000USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-23,400,000USD91
2026-01-01 to 2026-06-30-54,256,000USD181
2025-01-01 to 2025-06-30-58,396,000USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2026-01-01 to 2026-06-30319,000USD181
2025-01-01 to 2025-06-302,558,000USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,082,000USD91
2026-01-01 to 2026-06-303,381,000USD181
2025-04-01 to 2025-06-301,907,000USD91
2025-01-01 to 2025-06-303,536,000USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-301,736,000USD181
2025-01-01 to 2025-06-301,325,000USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2026-01-01 to 2026-06-3038,144,000USD181
2025-01-01 to 2025-06-3062,264,000USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-1,595,681,000USD
At 2025-12-31-1,534,309,000USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-30120,397,390shares91
2026-01-01 to 2026-06-30120,215,028shares181
2025-04-01 to 2025-06-30118,528,046shares91
2025-01-01 to 2025-06-30118,452,214shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-30120,397,390shares91
2026-01-01 to 2026-06-30120,215,028shares181
2025-04-01 to 2025-06-30118,528,046shares91
2025-01-01 to 2025-06-30118,452,214shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.25USD/shares91
2026-01-01 to 2026-06-30-0.51USD/shares181
2025-04-01 to 2025-06-30-0.29USD/shares91
2025-01-01 to 2025-06-30-0.61USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.25USD/shares91
2026-01-01 to 2026-06-30-0.51USD/shares181
2025-04-01 to 2025-06-30-0.29USD/shares91
2025-01-01 to 2025-06-30-0.61USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-06-3051,546,000USD
At 2025-12-3156,925,000USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-31,134,000USD91
2026-01-01 to 2026-06-30-64,134,000USD181
2025-04-01 to 2025-06-30-36,968,000USD91
2025-01-01 to 2025-06-30-78,248,000USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-30157,953,000USD
At 2025-12-31208,704,000USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-3032,592,000USD
At 2025-12-3136,071,000USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-06-303,258,000USD
At 2025-12-312,656,000USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2026-06-30703,000USD
At 2025-12-31916,000USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-3033,216,000USD91
2026-01-01 to 2026-06-3067,515,000USD181
2025-04-01 to 2025-06-3038,875,000USD91
2025-01-01 to 2025-06-3081,784,000USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-3024,387,000USD91
2026-01-01 to 2026-06-3049,090,000USD181
2025-04-01 to 2025-06-3027,430,000USD91
2025-01-01 to 2025-06-3056,566,000USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-30116,694,106shares
At 2025-12-31115,359,735shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-301,749,116,000USD
At 2025-12-311,741,259,000USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-06-30-117,000USD
At 2025-12-31116,000USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2026-06-3040,554,000USD
At 2025-12-3141,609,000USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2026-06-3075,675,000USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2026-06-3014,904,000USD
At 2025-12-3120,024,000USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-303,480,000USD
At 2025-12-314,131,000USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2026-06-300USD
At 2025-12-31381,000USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-61,372,000USD181
2025-01-01 to 2025-06-30-71,691,000USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-308,829,000USD91
2026-01-01 to 2026-06-3018,425,000USD181
2025-04-01 to 2025-06-3011,445,000USD91
2025-01-01 to 2025-06-3025,218,000USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2026-01-01 to 2026-06-305,698,000USD181
2025-01-01 to 2025-06-306,611,000USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2026-04-01 to 2026-06-30975,000USD91
2026-01-01 to 2026-06-302,762,000USD181
2025-04-01 to 2025-06-302,898,000USD91
2025-01-01 to 2025-06-306,557,000USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-213,000USD181
2025-01-01 to 2025-06-30-2,144,000USD181

Inspect the source

Entity
FATE THERAPEUTICS INC / CIK 0001434316
Captured
2026-09-20T09:02:50.083Z
SEC response SHA-256
0d3cfe19fd70310e30c155481681c8ab78f983607cbe93ec4d5e89a1219f24a2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001434316.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))